Clinical Trial Update: Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures [Phase 3]

View source ↗

Summary

A Phase 3 trial of Remodulin (treprostinil) for critical limb ischemia without planned revascularization has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Vascular Disease

Drugs mentioned

• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Critical Limb Ischemia, Peripheral Vascular Disease | Phase 3 | Status: TERMINATED